Abstract
The lower-airway microbiome may influence the pathogenesis of lung disease. Bronchopulmonary dysplasia (BPD) is a serious morbidity associated with preterm birth that may be influenced by lower-airway microbial or metabolic alterations. This study used16S rRNA gene sequencing, metabolomic analyses, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database to investigate the lower-airway microbiome and metabolome in a cohort of preterm infants with mild, moderate, or severe BPD or no BPD. Differences in the diversity and composition of the infants’ lower airway microbiota, as well as metabolic status, were initially observed, but became less pronounced at 7 days of life. Decreased diversity of the lower-airway microbiome, increased abundance of Stenotrophomonas, and increased level of sn-glycerol 3-phosphoethanolamine were associated with increased BPD severity, and have potential as predictive biomarkers for BPD. Stenotrophomonas may contribute to the development of BPD and influence the composition of the lower-airway microbiome through its metabolite, sn-glycerol 3-phosphoethanolamine. These findings provide novel insights into the lower-airway microbiome and its role in BPD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Natural Science Foundation of China Fund Project (No. 81571483, 81971431), Shenzhen Science and Technology Innovation Free Exploration Project (JCYJ20170817100735621), Shenzhen Synthetic Biology Innovation Research Institute, Chinese Academy of Sciences, Opening to the Outside World Fund Project (DWKF20190008), Scientific Research Fund of Shenzhen University General Hospital (SUGH2020QD003).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Chongqing Medical University approved the protocol.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript is available.
